Honokiol: A potent chemotherapy candidate for human colorectal carcinoma

Fei Chen, Tao Wang, Yi-Feng Wu, Ying Gu, Xiao-Li Xu, Shu Zheng, Xun Hu

INTRODUCTION

In traditional Chinese medicine, Houpu (Magnolia officinalis) has long been one of the important herbs. It is widely used by Chinese people in treating thrombotic stroke, typhoid fever, anxiety and nervous disturbance[11] when used in combination with other herbs. With its major active constituent extracted from the bark of Houpu, honokiol has been found having a variety of pharmacological effects, such as anti-inflammatory[2], antithrombotic[3], anti-arrhythmic[4], antioxidative[5] and anxiolytic effects[6]. Recently, honokiol has been reported to exhibit a potent cytotoxicity by inducing cell apoptosis in rat and human leukemia cells[7-8], human fibrosarcoma cells[9], human squamous lung cancer CH27 cells[10] and human SVR angiosarcoma cells[11], yet there has been no report on honokiol in the treatment of human colorectal carcinoma.

Previous studies have shown that honokiol can induce apoptosis with characteristic morphological changes and DNA fragments, involvement of Caspase family and Bcl-2 family[10]. It could reduce tumor volume of SVR angiosarcoma in nude mice[10]. However, it is still unclear whether honokiol can be used as a monomer in clinic. In this study, we chose colorectal carcinoma cells to investigate its possible application in clinical practice.

METHODS

In vitro anticancer activity of honokiol was demonstrated by its induction of apoptosis in tumor cells. We analyzed cell proliferation with MTT assay, cell cycle with flow cytometer, DNA fragment with electrophoresis on agarose gels. To test the mechanism of honokiol-induced apoptosis, Western blotting was used to investigate the factors involved in this process. The pharmacokinetics study of honokiol was tested by high phase liquid chromatography. In vivo study, Balb/c nude mice were incubated with RKO cells. Honokiol was injected intraperitoneally every other day into tumor bearing Balb/c nude mice.

RESULTS: Our results showed that honokiol induced apoptosis of RKO cells in a time- and dose-dependent manner. At 5-10 ug/mL for 48 h, honokiol induced apoptosis through activating Caspase cascades. Pharmacokinetics study demonstrated that, honokiol could be absorbed quickly by intraperitoneal injection, and maintained in plasma for more than 10 h. In nude mice bearing RKO-incubated tumor, honokiol displayed anticancer activity by inhibiting tumor growth and prolonging the lifespan of tumor bearing mice.

CONCLUSION: With its few toxicity to normal cells and potent anticancer activity in vitro and in vivo, honokiol might be a potential chemotherapy candidate in treating human colorectal carcinoma.

Chen F, Wang T, Wu YF, Gu Y, Xu XL, Zheng S, Hu X. Honokiol: A potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol 2004; 10(23): 3459-3463 http://www.wjgnet.com/1007-9327/10/3459.asp

INTRODUCTION

In traditional Chinese medicine, Houpu (Magnolia officinalis) has long been one of the important herbs. It is widely used by Chinese people in treating thrombotic stroke, typhoid fever,
(Olympus) and imaged with a digital camera. To detect DNA fragmentation, the cells were collected and lysed with lysis buffer containing 50 mmol/L Tris-HCL (pH 7.5), 20 mmol/L EDTA, and 10 g/L NP-40. Then 10 g/L SDS and RNase (5 µg/mL) were added to the supernatants, and incubated at 56 °C for 2 h, followed by incubation with proteinase K (2.5 µg/mL) at 37 °C for 2 h. After the DNA was precipitated by addition of both ammonium acetate (3.3 mol/L) and ethanol (99.5 %), it was dissolved in a loading buffer. DNA fragmentation was detected by electrophoresis on 15 g/L agarose gels and was visualized with ethidium bromide staining.

**Cell cycle analysis by FCM**
Honokiol-treated RKO cells and vehicles were fixed with 700 mL/L alcohol for 15 min at 4 °C, then stained with 1.0 µg/mL propidium dodide (PI, Sigma, USA). The red fluorescence of DNA-bound PI in individual cells was measured at 488 nm with propidium dodide (PI, Sigma, USA). The red fluorescence of DNA-bound PI in individual cells was measured at 488 nm.

**Western blot assay**
RKO cells (5×10⁵) were lysed by 4 g/L trypsin containing 0.2 g/L EDTA, then collected after washed twice with phosphate-buffered saline (PBS, pH 7.4). Total protein extracts from the cells were prepared using cell lysis buffer [150 mmol/L NaCl, 0.5 mol/L Tris-HCL (pH 7.2), 0.25 mol/L EDTA (pH 8.0), 10 g/L Triton X-100, 50 mL/L glycerol, 12.5 g/L SDS]. The extract (30 µg) was electrophoresed on 120 g/L SDS-PAGE gel and electroblotted onto polyvinylde difluoride membrane (PVDF, Millipore Corp., Bedford, MA) for 2 h in a buffer containing 25 mmol/L Tris-HCL for 2 h, followed by incubation with proteinase K (2.5 µg/mL) at 37 °C for 2 h. After the DNA was precipitated by addition of both ammonium acetate (3.3 mol/L) and ethanol (99.5 %), it was dissolved in a loading buffer. DNA fragmentation was detected by electrophoresis on 15 g/L agarose gels and was visualized with ethidium bromide staining.

**Cell toxicity on primary cells**
Primary human fibroblast cells were derived from fresh skin[13]. Human monocytes were isolated from umbilical blood by Ficoll-Hyake separation method while seeded in 96-well microplates. Primary human fibroblast cells were derived from fresh skin[13]. HUVECs isolated from fresh human umbilical cords were inoculated into 96-well microplates at 5,000 cells/well[14]. Following treatment with the concentrations of 5, 10, 20, 40 µg/mL of honokiol for 24 h, cell viability was estimated by trypan blue exclusion. Three wells were measured at each time point/concentration. Six wells were measured for each concentration of test compound. All toxicity experiments were at least repeated three times.

**Pharmacokinetics study**
For intraperitoneal (ip) pharmacokinetics study, honokiol was mixed with PEG400/dextrose by 7:3 in volume at a concentration of 20 g/L. Thirty Balb/c mice received honokiol by ip at a dose of 250 mg/kg. Blood samples were collected as described[16]. The plasma concentrations were tested by the total fluorescence intensity at 290 nm with high phase liquid chromatograph (HPLC, HEWLETT PACKARD)[17]. Chromatography was carried out using a Hypersil C18 column (5 mm×100 mm×2.1 mm) with a flow rate of 0.2 mL/min. Pharmacokinetic parameters were estimated by Modkine programs (Biosoft, UK).

**In vivo efficacy evaluation**

**Effect of honokiol on ascites formation in Balb/c nude mice**
Five Balb/c nude mice in each group were transplanted with 1×10⁷ RKO cells by ip. Honokiol was dissolved in PEG400/ Tween 20 (9:1 by volume). Honokiol-treated group was intragastrically administered 2 mg of honokiol per mice on d 0, 2, 4, 6, 8 and 10 after inoculation of RKO cells. While the control group was given the same volume of PEG400/Tween20. Animals were regularly monitored for the appearance of peritoneal bulge and body weight.

**Effect of honokiol on solid tumor growth in Balb/c nude mice**
RKO cells (5×10⁶) were injected subcutaneously at the axilla of Balb/c nude mice. When tumors became visible about one week after implant, the animals were randomized into four groups: Adriamycin-treated, honokiol-treated, vehicle and control. All mice received ip injection on days 8-11, 14-17, 21-24 and 28-31. Each mouse of honokiol-treated group received 80 mg/kg/d of honokiol suspended in PEG400/dextrose (7:3 by volume) intraperitoneally, while vehicle given equivalent solvent of PEG400/dextrose. Adriamycin dissolved in saline was injected ip at a dose of 2 mg/kg. Mice of control group were given the same volume of saline. Tumor growth was monitored with calipers every other day, and tumor volume was calculated using the modified ellipsoid formula: A/6×AxB², where A is the longer axis and B is the axis perpendicular to A (Figure 1)[19].

**Statistical analysis**
Values were given as mean±SD. Statistical comparisons were made by Student’s t-test, and P<0.05 was taken as significant.

**RESULTS**

**Inhibition of RKO cell proliferation**
Cells treated with honokiol resulted in a dose- and time-dependent cytotoxicity in RKO cells. As shown in Figure 2A, honokiol-mediated cytotoxicity occurred at the concentration of 5 µg/mL and above. A significant decrease in cell number was seen at 10 µg/mL. The concentration leading to a 50% decrease in cell number was seen at 10 µg/mL. The concentration leading to a 50% decrease in cell number (IC50) was about 12.47 µg/mL. Moreover, treatment of RKO cells with honokiol resulted in a dose- and time-dependent cytotoxicity in RKO cells. As shown in Figure 2A, honokiol-mediated cytotoxicity occurred at the concentration of 5 µg/mL and above. A significant decrease in cell number was seen at 10 µg/mL. The concentration leading to a 50% decrease in cell number (IC50) was about 12.47 µg/mL. Moreover, treatment of RKO cells with honokiol resulted in a significant growth inhibition at various time points (Figure 2B).

**Morphological changes and DNA fragmentation detection in RKO cells**
According to MTT results, we chose 5, 10, 15 µg/mL of honokiol to detect molecular changes. Under an inverted phase contrast microscope, honokiol-treated cells exhibited morphological features of apoptosis (Data not shown): rounded and granulated morphology, some vacuoles coming from cytoplasm, cell shrinkage and eventually detached from culture plates. In honokiol-treated cells, a degradation of chromosomal DNA into small internucleosomal fragments was evidenced by the formation of 180-200 bp DNA ladders on agarose gels (Figure 3), hallmark of cells undergoing apoptosis. No DNA ladders were detected in the samples isolated from control cultures. These results indicated that honokiol induced an apoptotic cell death in RKO cells.
**Effect of honokiol on cell cycle analysis of RKO cells**

RKO cells were exposed to increasing concentrations of honokiol (5-15 µg/mL) for 48 h, and the growth of cells was analyzed with flow cytometry. In the absence of honokiol, the cell populations were at G1, S, and G2/M phases (Figure 4), accompanied with increased concentrations of honokiol by a concomitant increase of the G1 phase (Table 1). From Figure 4, the peak areas of subdiploid were enlarged with increased concentrations of honokiol. This observation led to a suggestion of G1 arrest. DNA fragmentation was seen when the cells were exposed to honokiol at 10 µg/mL and above (14.10% and 20.31%, respectively).

**Table 1** Effect of honokiol on cell cycle distribution and apoptosis of RKO cells

| Groups          | Cell cycle distribution (%) | Apoptosis (%) |
|-----------------|-----------------------------|---------------|
|                 | G0/G1          | S         | G2/M | Apoptosis (%) |
| Control         | 44.45          | 45.10    | 10.14 | 0.27          |
| 5 µg/mL         | 48.03          | 42.37    | 9.60  | 4.51          |
| 10 µg/mL        | 54.04          | 40.30    | 5.66  | 14.10<sup>a</sup> |
| 15 µg/mL        | 58.94          | 39.36    | 1.70  | 20.31<sup>b</sup> |

<sup>a</sup>P<0.05, <sup>b</sup>P<0.01 vs corresponding control group. Cell cycle distribution was determined after 48 h of treatment in each group. The tabulated percentages were an average calculated on the results of three separate experiments. The results were represented by mean±SD (n = 3).

**Caspase -3 and -9 expression by Western blot**

Since Caspases are the main factors in the apoptotic pathway, we investigated whether Caspases were involved in inducing apoptosis of RKO cells treated with honokiol. Cells induced for 48 h were analyzed for protein expression by Western blot. The results showed that Caspase-3 and -9 were up-regulated in a dose-dependent manner (Figure 5).

**Effects of honokiol on primary cultured cells**

As shown in Figure 6, honokiol had little cytocidal effect on primary human fibroblast cells and human lymphocytes even up to 40 µg/mL. HUVEC cells after honokiol treatment resulted in a sharply dose-dependent cytotoxicity. These
results demonstrated that human fibroblast cells and lymphocytes were more resistant to the honokiol-mediated cytotoxicity than HUVECs.

Figure 5 Western blot analysis for the expression of Caspase-3 and -9 in human colorectal carcinoma cell line RKO cells. Lane 1: vehicle; lane 2: 5 µg/mL; lane 3: 10 µg/mL.

Figure 6 Cytocidal effect of honokiol on the growth of primary cultured human umbilical vein endothelial cells, primary human fibroblast cells and human lymphocytes.

**Pharmacokinetics studies**

The pharmacokinetics of honokiol was evaluated after intraperitoneal injection of 250 mg/kg to BALB/c mice. The maximum plasma concentration of honokiol was observed at 27.179±6.252 min after administration (Figure 7). The plasma disappearance curve could best be described by a first-order absorption one-compartment model, with an absorption half-life of 10.121±2.761 min, and an elimination half-life of 27.179±6.252 min after administration (Figure 7).

Figure 7 Honokiol concentration in plasma of BALB/c mice.

**Inhibition of tumor growth in nude mice implanted with RKO cells**

We studied the effect of honokiol on the growth of RKO tumor. There was significant inhibition of tumor growth by honokiol (Table 2). All the control mice developed peritoneal bulge and died by d 12. However, no peritoneal bulge was observed in 80% of the honokiol-treated animals and the mice survived for up to 30 d. These observations indicated the anti-tumor activity of honokiol in vivo (Table 2).

![Graph](image)

**Table 2** Effect of honokiol on ascerts growth of tumor in Balb/c nude mice

| Group     | Ascites | MST (d) | Dead | Living | Survival percentage |
|-----------|---------|---------|------|--------|--------------------|
| Control   | 5       | 10.7    | 5    | 0      | 0%                 |
| Honokiol  | 1       | 34.3    | 1    | 4      | 80%                |

**Table 3** Effect of honokiol on MST and T/C% in Balb/c nude mice bearing RKO-incubated tumor

| Group     | Number of mice | MST (d) | T/C (%) |
|-----------|----------------|---------|---------|
| Control   | 7              | 28.8    | 100     |
| Vehicle   | 6              | 29.7    | 104.5   |
| Adriamyacin | 7           | 46.2a   | 160.4b  |
| Honokiol  | 7              | 50.9a   | 176.7b  |

MST: Mean survival time. RKO cells were transplanted intraperitoneally. Honokiol was administered 2 mg per mice on d 0, 2, 4, 6, 8, and 10 after tumor transplantation. The mice were monitored for peritoneal bulge and survived for up to 30 d. Control mice died by d 12 of RKO inoculation.

**Inhibition of solid tumor growth in nude mice bearing RKO cells**

From Figure 8, animals in control and vehicle groups showed a progressive increase in tumor volume, with a growth rate of 1627.6% and 1408.2% respectively on d 28. While in treated groups, tumor growth rate was increased to 968.9% in adriamycin group and 709.9% in honokiol-treated group. There was a significant difference between honokiol-treated group and its control (treated with PEG400/dextrose) (P<0.05). Similar results were found between adriamycin-treated group and its control (P<0.05). These data further confirmed that honokiol had an effective anticancer activity in vivo.

Figure 8 Effect of honokiol on the growth of xenografted RKO in Balb/c nude mice. The Y-axis represents tumor volume, X-axis represents time (day) after RKO cell inoculation.

**Prolongation of life-span in nude mice bearing RKO solid tumor**

The lifespan of mice in honokiol-treated group (80 mg/kg) was monitored and compared to the vehicle and adriamycin-treated group (Table 3). The mean survival time was 50.9 d in honokiol-treated group, with a significant prolongation compared to vehicle group (29.7 d, P<0.05). The survival rate in honokiol-treated group was 176.7%, much higher than that in vehicle group (P<0.01).

There was no significant difference between control and vehicle groups and between adriamycin-treated and honokiol-treated groups. The results demonstrated that honokiol had a similar effect to adriamycin in prolongation of lifespan of tumor-bearing nude mice.

**Table 3** Effect of honokiol on MST and T/C% in Balb/c nude mice bearing RKO-incubated tumor

| Group     | Number of mice | MST (d) | T/C (%) |
|-----------|----------------|---------|---------|
| Control   | 7              | 28.8    | 100     |
| Vehicle   | 6              | 29.7    | 104.5   |
| Adriamyacin | 7           | 46.2a   | 160.4b  |
| Honokiol  | 7              | 50.9a   | 176.7b  |

MST, mean survival time. The survival rate (T/C%) was calculated according to the following equation: T/C (%) = [average survival period in the test group/average survival period in the control group]×100. aP<0.05; bP<0.01 vs vehicle or control.
DISCUSSION
Many anticancer drugs kill tumor cells by inducing apoptosis. Previous studies suggest that growth inhibition by honokiol resulted from the induction of apoptosis in several cell lines\(^1\)\(^\text{(11)}\). A further study reported that in human squamous lung cancer cells, honokiol induced apoptosis by down-regulating Bcl-X, and sequentially activating Caspase cascade\(^2\)\(^\text{(10)}\). Our results confirmed this honokiol-mediated apoptotic progression in cultured RKO cells.

A variety of compounds with potent anticancer activity in vitro could not be used in clinic, one probable reason was due to their strong toxicities to normal cells\(^3\)\(^\text{(17,18)}\). Therefore, we first investigated honokiol’s effects on the toxicity of primary cultured human cells. Our data demonstrated that the IC50s were much higher in human fibroblasts and lymphocytes than in RKO cells, with the exception that HUVECs were more sensitive to honokiol. The safe doses for fibroblasts and lymphocytes could be up to 40 µg/mL (Figure 6), much greater than that for RKO and other tumor cells (data not shown). The phenomenon that primary cultured endothelial cells were more sensitive to honokiol might be related to the finding that honokiol had antiangiogenesis activity by inhibiting VEGF and its receptor 2 in vitro\(^4\)\(^\text{(11)}\). In chemotherapy, antiangiogenesis is another important target besides apoptosis induction in tumor cells. Based on the fewer toxicity to normal fibroblasts and lymphocytes, we thus proposed that honokiol could be a safe and potent candidate of chemotherapy for colorectal cancer in vivo.

Another major obstacle was that many potent agents were poorly absorbed and quickly cleared in vivo, such as curcumin. Curcumin was difficult to absorb in the gastrointestinal tract and was poorly absorbed and quickly cleared after oral administration. Another major obstacle was that many potent agents were poorly absorbed and quickly cleared in vivo, such as curcumin. Curcumin was difficult to absorb in the gastrointestinal tract and was poorly absorbed and quickly cleared after oral administration. Curcumin was difficult to absorb in the gastrointestinal tract and was poorly absorbed and quickly cleared after oral administration.

We then established two in vivo models with Babl/c nude mice bearing RKO cells, the ascitic tumor model and the solid tumor model. In RKO ascitic tumor model, honokiol exhibited a strong efficiency in prolonging the lifespan of ascitic tumor bearing mice and was highly effective on inhibiting intraperitoneal ascites in Babl/c nude mice. In our another model, honokiol also exhibited a potent efficiency in inhibiting solid tumor growth. In RKO incubated tumor bearing mice, honokiol at 80 mg/kg significantly inhibited the tumor growth and prolonged the lifespan compared to the vehicle \((P<0.05)\). The antitumor efficiency of honokiol was similar to that of the commonly used chemotherapy drug, Adriamycin.

The results of the present study are encouraging because honokiol has shown significant inhibition of tumor growth in vitro and in vivo, as well as prolongation of lifespan in tumor-bearing mice in vivo. Together with its safety to human, honokiol might be a promising chemotherapy candidate in treating colorectal carcinoma or other cancers in clinic.

REFERENCES
1 Squires RE, Ai J, Witt MR, Kahnberg P, Saederup E, Sterner O, Nielsen M. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. Neurochem Res 1999; 24: 1593-1602
2 Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 2003; 475: 19-27
3 Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, Hsu HY. Two antiplatelet agents from Magnolia officinalis. Thromb Res 1988; 50: 757-765
4 Liou KT, Lin SM, Huang SS, Chih CL, Tsai SK. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med 2003; 69: 130-134
5 Lo YC, Teng CM, Chen CF, Chen CC, Hong CY. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 1994; 47: 549-553
6 Kuribara H, Kishi E, Hattori N, Yuzurihara M, Maruyama Y. Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of magnolia. Phytother Res 1999; 13: 593-596
7 Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemia HL-60 cells. Life Sci 1994; 55: 1061-1069
8 Hibasami H, Achiwa Y, Katsuzaki H, Imai K, Yoshioka K, Nakanishi K, Ishii Y, Hasegawa M, Komita T. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 1998; 2: 671-673
9 Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med 2001; 67: 705-708
10 Yang SE, Hsieh MT, Tsai TH, Hsu SL. Down-modulation of Bcl-2, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol 2002; 63: 1641-1651
11 Bai X, Cerimelle F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003; 278: 35501-35507
12 Arbiser JL, Panigrahy D, Klauber N, Rupnick M, Flynn E, Udagawa T, D’Amato RJ. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999; 40(6 pt 1): 925-929
13 LaMontagne KR Jr, Moses MA, Wiederschain D, Mahajan S, Moses MA, Wiederschain D, Mahajan S. Association between soft agar growth and in vitro angiogenesis in angiosarcoma cells. Am J Pathol 2000; 157: 1937-1945
14 Beddy D, Watson RW, Fitzpatrick JM, O’Connell PR. Increased vascular endothelial growth factor production in fibrosarcoma isolated from strictures in patients with Crohn’s disease. Br J Surg 2004; 91: 72-77
15 Graafensen MH, Gannon PJ, Lutz M, Hløyoke ED. Isolation of human peripheral blood lymphocytes: modification of a double discontinuous density gradient of Ficoll-Hypaque. J Immunol Methods 1977; 14: 15-17
16 Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1997; 94: 2620-2625
17 Tsai TH, Chou CJ, Cheng FC, Chen CF. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J Chromatogr B Biomed Anal 1994; 655: 41-45
18 Eikelsdal HP, Bjerkvig R, Dahl O. Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 2001; 51: 355-354

Edited by Wang XL. Proofread by Zhu LH and Xu FM